Skip to main content
SpringerLink
Log in

Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III–IV malignant melanoma

  • Article
  • Published:
Pathology & Oncology Research

Abstract

5-S-cysteinyldopa is a precursor of pheomelanin. S-100B protein is a low molecular weight, acidic, calcium binding, cytoplasmatic protein. LDH was defined as the most important serum parameter in disseminated melanoma. The aim of the present study was to compare the prognostic values of serum 5-S-Cysteinyldopa, S-100B and LDH concentrations in Stage III–IV melanoma patients. Serum samples were taken from 179 Stage III–IV melanoma patients at diagnosis. Serum 5-S-CD concentrations were determined by HPLC, S-100B protein by immunoluminometric assay while LDH by UV kinetic method. The mean/median concentrations of LDH, S-100B protein and 5-S-CD in Stage III patients ranged around the normal level. In Stage IV, the markers ranked as S100B = 5-S-CD > LDH for sensitivity, S-100B > LDH > 5-S-CD for specificity and LDH = S100B = 5-S-CD for positive predictive value, respectively. Furthermore, mean marker concentrations of patients with progressive disease differed significantly from nonprogresssive cases (when staging categories have been disregarded). Survival analysis indicated, that the initially elevated LDH and S-100B level in Stage IV disease predicts comparably short survival. Results of our study suggest that these serum marker values correlate well with Stages and disease progression. In Stage IV melanoma, the markers had appropriate sensitivity, high specificity as well as important positive predictive value. Among the studied serum markers S-100B protein and LDH proved to be similarly reliable in respect to the clinical outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Balch CM, Buzaid AC, Atkins MB et al: A new American Joint Committee on cancer staging system cutaneous melanoma. Cancer 88: 1484–1491, 2000

    Article  PubMed  CAS  Google Scholar 

  2. Bánfalvi T, Gilde K, Boldizsár M, et al: Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression. Pathol Oncol Res 5: 218–223, 1999

    Article  PubMed  Google Scholar 

  3. Bánfalvi T, Gilde K, Boldizsár M, et al: Serum concentration of 5-S-cysteinyldopa in patients with melanoma. Eur J Clin Invest 30: 900–904, 2000

    Article  PubMed  Google Scholar 

  4. Benathan M, Labidi F: Modulation of 5-S-cysteinyldopa formation by tyrosinase activity and intracellular thiols in human melanoma cells. Melanoma Res 6: 183–189, 1996

    Article  PubMed  CAS  Google Scholar 

  5. Berking C, Schlüpen E, Schrader A, et al: Tumor markers in peripheral blood of patients with malignant melanoma: Multimarker RT-PCR versus a luminometric assay for S-100. Arch Dermatol Res 291: 479–484, 1999

    Article  PubMed  CAS  Google Scholar 

  6. Buer J, Probst M, Franzke A et al: Elevated serum levels of S100 and survival in metastatic malignant melanoma. Br J Cancer 75: 1373–1376, 1997

    PubMed  CAS  Google Scholar 

  7. Buzaid AC, Ross MI, Balch CM, et al: Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of new staging system. J Clin Oncol 15: 1039–1051, 1997

    PubMed  CAS  Google Scholar 

  8. Clark WH Jr,From L, Bernardino EA, Mihm MC: The histogenesis and biologic behaviour of primary human malignant melanomas of the skin. Cancer Res 29: 705–726, 1991

    Google Scholar 

  9. Deichmann M, Benner A, Bock Mjackel A, et al: S-100 beta, melanoma inhibiting activity and lactate dehydrogenase discriminate progressive from nonprogressive AJCC Stage IV melanoma. J Clin Oncol 17: 1891–1896, 1999

    PubMed  CAS  Google Scholar 

  10. Deichmann M, Benner A, Kuner N et al: Are responses to therapy of metastatized melanoma reflected by decreasing serum values of S-100 beta or MIA? Melanoma Res. 11: 291–296, 2001

    Article  PubMed  CAS  Google Scholar 

  11. Djukanovic D, Hofmann U, Sucker A, et al: Comparison of S100 protein and MIA protein as serum markers in malignant melanoma. Anticancer Res 20: 2203–2207, 2000

    PubMed  CAS  Google Scholar 

  12. Franzke A, Probst-kepper M, Buer J, et al: Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer 78: 40–45, 1998

    PubMed  CAS  Google Scholar 

  13. Guo HB, Stoffel-Wagner B, Bierwirth T, et al: Clinical significance of serum S-100 in metastatic malignant melanoma. Eur J Cancer 31A: 1898–1902, 1995

    Article  PubMed  CAS  Google Scholar 

  14. Hansson C, Edholm L, Agrup G, et al: The quantitative determination of 5-S-cysteinyldopa and dopa in normal serum and in serum from patients with malignant melanoma by means of high performance liquid chromatography. Clin Chim Acta 88: 419–421, 1978

    Article  PubMed  CAS  Google Scholar 

  15. Hasegawa M, Takata M, Hatta N, Wakamatsu K, et al: Simultaneous measurement of serum 5-S-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma. Melanoma Res 7: 243–251, 1997

    Article  PubMed  CAS  Google Scholar 

  16. Hauschild A: The use of serological tumor markers for malignant melanoma. Onkologie 20: 462–465, 1997

    Article  Google Scholar 

  17. Hauschild A, Michaelsen J, Brenner W, et al: Prognostic significance of serum S-100B detection compared to routin blood parameters in advanced metastatic melanoma patients. Melanoma Res 9: 155–161, 1999

    Article  PubMed  CAS  Google Scholar 

  18. Horikoshi T, Ito Sh, Wakamatsu K, et al: Evaluation of melaninrelated metabolites as markers of melanoma progression. Cancer 73: 629–636, 1994.

    Article  PubMed  CAS  Google Scholar 

  19. Karnell R, von Schoultz E, Hansson LO, et al.: S 100 B protein, 5-S-cysteinyldopa and 6-hydroxy-5-metoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma. Melanoma Res 7: 393–399, 1997

    Article  PubMed  CAS  Google Scholar 

  20. Karnell R, Kagedal B., Lindholm C, et al: The value of cysteinyldopa in the follow up of disseminated malignant melanoma. Melanoma Res 10: 363–369, 2000

    Article  PubMed  CAS  Google Scholar 

  21. Krahn G, Kaskel P, Sander S, et al: S-100 beta is a more reliable tumor marker in peripherial blood of patients with newly occurred melanoma metastases comparing to MIA, albumin and lactat dehydrogenase. Anticancer Res 21: 311–1316, 2001

    Google Scholar 

  22. Martenson ED, Hansson LO, Nilsson B, et al.: Serum S-100b protein as prognostic marker in malignant cutaneuos melanoma. J Clin Oncol 19: 824–831, 2001

    PubMed  CAS  Google Scholar 

  23. Meyerhoffer S, Lindberg Z, Hager A, et al: Urinary excretion of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in children. Acta Derm Venereol 78: 31–35, 1998

    Article  PubMed  CAS  Google Scholar 

  24. Sasaki Y, Shimizu H, Naka W, et al: Evaluation of the clinical usefulness of measuring urinary excretion of 5-S-cysteinyldopa in melanoma: ten years experience of 50 patients. Acta Derm Venerol 77: 379–381, 1998

    Google Scholar 

  25. Seregeni E, Massaron S, Martinetti A, et al: S-100 protein serum levels in cutaneous malignant melanoma. Oncol Rep 5: 601–604, 1998

    Google Scholar 

  26. Schmitz C, Brenner W, Henze E, et al: Comparative study on the clinical use of protein S-100 B and MIA in melanoma patients. Anticancer Res 20: 5059–5063, 2000

    PubMed  CAS  Google Scholar 

  27. Schoultz ES, Diepgen TL, von den Dresch P: Clinical prognostic relevance of serum S-100b protein in malignant melanoma. Br J Dermatol 38: 426–430, 1998

    Article  Google Scholar 

  28. Wakamatsu K, Ito S: Seasonal variations in serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxyl acid in healthy Japanese. Pigment Cell Res 8: 132–134, 1995

    Article  PubMed  CAS  Google Scholar 

  29. Wibe E, Hannisdal E, Paus E, Aamdal S: Neuron-specific enolase as prognostic factor in metastatic melanoma. Eur J Cancer 28: 1692–1695, 1992

    Article  Google Scholar 

  30. Wimmer I, Meyer CJ, Seifert B, et al: Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemoterapy. Cancer Res 57: 5073–5076, 1997

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, National Institute of Oncology, Rath György u.7-9, H-1122, Budapest, Hungary

    Teodóra Bánfalvi & Katalin Gilde

  2. Department of Biochemistry, National Institute of Oncology, Budapest, Hungary

    Mariann Boldizsár & Tibor Kremmer

  3. Central Clinical Laboratory, National Institute of Oncology, Budapest, Hungary

    Maria Gergye & Szabolcs Ottó

Authors
  1. Teodóra Bánfalvi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mariann Boldizsár
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Gergye
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Katalin Gilde
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tibor Kremmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Szabolcs Ottó
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Teodóra Bánfalvi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bánfalvi, T., Boldizsár, M., Gergye, M. et al. Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III–IV malignant melanoma. Pathol. Oncol. Res. 8, 183–187 (2002). https://doi.org/10.1007/BF03032392

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03032392

Keywords

Search

Navigation